Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Accumulated Expenses (2023 - 2025)

Bioregenx (BRGX) has 3 years of Accumulated Expenses data on record, last reported at $380599.0 in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 0.86% year-over-year to $380599.0; the TTM value through Sep 2025 reached $380599.0, down 0.86%, while the annual FY2024 figure was $424277.0, 45.21% up from the prior year.
  • Accumulated Expenses reached $380599.0 in Q3 2025 per BRGX's latest filing, down from $405495.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $459732.0 in Q1 2025 and bottomed at $292190.0 in Q4 2023.
  • Average Accumulated Expenses over 3 years is $383269.2, with a median of $390982.0 recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: soared 45.21% in 2024, then dropped 0.86% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $292190.0 in 2023, then skyrocketed by 45.21% to $424277.0 in 2024, then fell by 10.29% to $380599.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $380599.0 in Q3 2025, $405495.0 in Q2 2025, and $459732.0 in Q1 2025.